Unknown

Dataset Information

0

New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.


ABSTRACT: Type 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future.

SUBMITTER: Cabello-Olmo M 

PROVIDER: S-EPMC6801436 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.

Cabello-Olmo Miriam M   Araña Miriam M   Radichev Ilian I   Smith Paul P   Huarte Eduardo E   Barajas Miguel M  

International journal of molecular sciences 20190926 19


Type 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destru  ...[more]

Similar Datasets

| S-EPMC4688091 | biostudies-literature
| S-EPMC8185359 | biostudies-literature
| S-EPMC5295319 | biostudies-literature
| S-EPMC5096826 | biostudies-literature
| S-EPMC5908887 | biostudies-literature
| S-EPMC4995772 | biostudies-literature
| S-EPMC4165040 | biostudies-literature
| S-EPMC5533303 | biostudies-literature
| S-EPMC4825862 | biostudies-literature
| S-EPMC4630527 | biostudies-literature